

NO headers, footers or page numbers

**SF424 Research Plan – E-forms  
OUTLINE for grants (effective 1-25-18)**

*If you do not use that section—skip that number, no blank page needed. For example for a new grant start with #2.*

**Research Plan Section**

1. Introduction to Application (1 page for resubmissions or revisions only)
2. **Specific Aims (page limit=1)**
3. **\*\*Research Strategy (R01=12 pages; R21 = 6) Be sure to include Rigor and Reproducibility here!**
4. Progress Report Publication List—NOT USED

**Human Subjects Sections –ALL MOVED to HS/CT form....new (see next page)!**

**Other Research Plan Sections**

5. Vertebrate Animals
6. Select Agent Research
7. Multiple PI Leadership Plan
8. Consortium/Contractual Arrangements
9. **Letters of Support (external letters) – In one long PDF**
10. Resource Sharing Plan(s) - *All investigator-initiated applications with direct costs of \$500,000 or greater (exclusive of consortium F&A) in any single year are expected to address data-sharing in their application.*
11. Authentication of Key Biological and/or Chemical Resources **\*\* (optional—only attach if needed)**

**Appendix (if applicable)**

16. Appendix –VERY limited review instructions!

**OTHER PROJECT INFORMATION** (No numbering for these!)

Cover Letter-optional –CANNOT include institute or study section requests—must go on PHS assignment for an end of grant!

**Abstract** (no more than 30 lines)

**Narrative** (3 sentences)

**Bibliography & References Cited** (no page limit)

**Facilities and other resources** (no page limit)

**Equipment** (no page limit)

**Budget justification**—No page limit—But check your RFA!

***New-Targeted enrollment form (online)***

NOTE: Also change in **Biosketches from D forms** –In Contribution to Science: limit 4 references per section  
limit =5 pages.

**2016-added—new form PHS Assignment Request**—use to select Institutes or study sections or list places you don't want the grant sent to!

NO headers, footers or page numbers

## New 2018- Human Subjects section:

### SECTION 1

1.1 \* Study Title (**limited to 30 characters**)

1.2. \* Is this Study Exempt from Federal Regulations? ☐ Yes ☐ No

1.3. Exemption Number ☐ 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8

### 1.4. \* Clinical Trial Questionnaire

If the answers to all four questions below are yes, this study meets the definition of a Clinical Trial.

1.4.a. Does the study involve human participants? ☒ Yes ☐ No

1.4.b. Are the participants prospectively assigned to an intervention? ☐ Yes ☐ No

1.4.c. Is the study designed to evaluate the effect of the intervention on the participants? ☐ Yes ☐ No

1.4.d. Is the effect that will be evaluated a health-related, biomedical, or behavioral outcome? ☐ Yes ☐ No

1.5. Provide the ClinicalTrials.gov Identifier (e.g., NCT87654321) for this trial, if applicable

optional

### SECTION 2

2.1. Conditions or Focus of Study---*Provide as WORD doc to cut and paste*

2.2. Eligibility Criteria---*Provide as WORD doc to cut and paste*

2.3 Age Limits---*need to fill in boxes*

2.4. Inclusion of Women, Minorities, and Children---*provide as a PDF*

2.5. Recruitment and Retention Plan---*provide as a PDF*

2.6. Recruitment Status: pull down menu

- ☐ Not yet recruiting
- ☐ Recruiting
- ☐ Enrolling by invitation
- ☐ Active, not recruiting
- ☐ Completed
- ☐ Suspended
- ☐ Terminated (Halted prematurely)
- ☐ Withdrawn (No participants enrolled)

2.7. Study Timeline---*provide as a PDF*

2.8. Enrollment of First Subject  Anticipated or Actual

**Inclusion Enrollment Reports**—planned or actual. ---These will need to be filled in on a PDF and then retyped into Cayuse

### SECTION 3

3.1. Protection of Human Subjects- provide as a PDF

IF Clinical Research—that's all that is needed

IF Clinical Trial.....continue!

NO headers, footers or page numbers

**For Clinical Trials only:**

3.2. Is this a multi-site study that will use the same protocol to conduct non-exempt human subjects research at more than one domestic site? ☐ Yes ☐ No ☐ N/A

If yes, describe the single IRB Plan --*provide as a PDF*

3.3. Data and Safety Monitoring Plan --*provide as a PDF*

3.4. Will a Data and Safety Monitoring Board be appointed for this study? ☐ Yes ☐ No

3.5. Overall Structure of the Study Team -- *provide as a PDF*

**SECTION 4**

4.1. Brief Summary—*In Word doc to cut and paste*

4.2. Study Design

4.2.a. Narrative Study Description

4.2.b. Primary Purpose :

- ☐ Treatment
- ☐ Prevention
- ☐ Diagnostics
- ☐ Supportive Care
- ☐ Screening
- ☐ Health Services Research
- ☐ Basic Science
- ☐ Device Feasibility
- ☐ Other

4.2.c. Interventions

NAME—*In Word doc to cut and paste*

DESCRIPTION—*In Word doc to cut and paste*

4.2.d. Study Phase

Is this an NIH-defined Phase III clinical trial? ☐ Yes ☐ No

4.2.e. Intervention Model  SINGLE GROUP, PARELLEL, CROSS-OVER, FACTORIAL, SEQUENTIAL, OTHER

4.2.f. Masking ☐ Yes ☐ No

☐ Participant ☐ Care Provider ☐ Investigator ☐ Outcomes Assessor

4.2.g. Allocation: N/A, Randomized or non-randomized

4.3. Outcome Measures: Select Primary, Secondary or Other

TIME FRAME -- *In Word doc to cut and paste*

BRIEF DESCRIPTION --*In Word doc to cut and paste*

4.4. Statistical Design and Power -- *provide as a PDF*

4.5. Subject Participation Duration—fill in box

4.6. Will the study use an FDA-regulated intervention? ☐ Yes ☐ No

4.6.a. If yes, describe the availability of Investigational Product (IP) and Investigational New Drug (IND)/Investigational Device Exemption (IDE) status -- *provide as a PDF*

4.7. Dissemination Plan -- *provide as a PDF*